Real-World Analysis of the Efficacy of Rebiopsy and<i>EGFR</i>Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer

Abstract

Approximately 60% of patients in the analyzed real-world cohort were eligible for tissue rebiopsy upon NSCLC progression. Osimertinib activity was higher in patients in whom T790M mutations were detected in tissues rather than in plasma samples.